SCHEMBL405131

SCHEMBL405131

Cc1ccc2nc(N3CCNCC3)c3nncn3c2c1F

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 9/20 0.46
HRH3 Q9Y5N1 2/20 0.46
KMT2A Q03164 2/20 0.45
POLB P06746 2/20 0.45
MAPK1 P28482 1/20 0.45
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 2/20 0.43
ESR1 P03372 1/20 0.43
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405908 0.87 HRH4 (0.61) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL437045 0.84 HRH4 (0.43) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL406075 0.79 MAPT (0.47) KMT2APOLBMAPK1HTR3EHTR3B
SCHEMBL12224924 0.77 HRH4 (0.50) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL405560 0.77 HRH4 (0.53) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL405849 0.77 HRH4 (0.53) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL12224925 0.77 HRH4 (0.50) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL2462963 0.76 HRH4 (0.61) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL404201 0.76 HRH4 (0.76) HRH4HRH3KMT2APOLBMAPK1
SCHEMBL405875 0.74 HRH4 (0.61) HRH4HRH3KMT2APOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 HRH4 1/4885HRH3 2/4885KMT2A 751/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 HRH4 1/4885HRH3 2/4885KMT2A 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.